Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| | 8-K | 10-K | 10-K | 10-K | 10-K | S-1/A |
| Revenues: |
| Dermatology | | 4.1 | 5.9 | 4.7 | 5.6 | 3.1 |
| Vascular | | 0.3 | 1.3 | 1.6 | 0.3 | |
| Other | | | | | | 2.8 |
| Total revenues [+] | 0.0 | 4.4 | 7.2 | 6.3 | 5.9 | 6.0 |
| Products | 0.0 | | | | | 3.8 |
| Services | | | | | | 2.2 |
| Revenue growth [+] | -99.5% | -38.8% | 15.1% | 6.6% | -1.8% | |
| Dermatology | | -30.0% | 25.9% | -16.1% | 78.8% | |
| Vascular | | -79.7% | -17.8% | 499.2% | | |
| Cost of goods sold [+] | 1.6 | 5.5 | 8.9 | 4.2 | 4.2 | 3.1 |
| Cost of product sales | 0.8 | | | | | 2.3 |
| Cost of services | 0.7 | | | | | 0.8 |
| Gross profit | -1.5 | -1.1 | -1.7 | 2.1 | 1.7 | 2.8 |
| Gross margin | -6990.9% | -24.4% | -22.9% | 32.8% | 29.0% | 47.5% |
| Selling, general and administrative | 15.5 | 26.0 | 51.5 | 30.4 | 14.9 | 5.3 |
| Research and development | 12.3 | 9.0 | 4.5 | 2.8 | 4.5 | 1.7 |
| EBITDA [+] | | -33.7 | -56.0 | -30.5 | -17.5 | -4.1 |
| EBITDA growth | -13.1% | -39.8% | 83.3% | 74.1% | 327.5% | |
| EBITDA margin | -133027.3% | -764.9% | -777.6% | -488.0% | -298.8% | -68.7% |
| Depreciation and amortization | | 2.4 | 1.8 | 0.6 | 0.2 | 0.1 |
| EBIT [+] | -29.3 | -36.1 | -57.7 | -31.2 | -17.8 | -4.2 |
| EBIT growth | -18.8% | -37.5% | 85.3% | 75.5% | 323.1% | |
| EBIT margin | -133027.3% | -818.6% | -801.9% | -498.0% | -302.6% | -70.2% |
| Interest income, net [+] | | 0.0 | 0.8 | 0.3 | 0.0 | 0.0 |
| Interest expense | | 0.1 | 0.3 | 0.0 | 0.0 | 0.0 |
| Interest income | | 0.1 | 1.0 | 0.4 | | |
| Other income (expense), net | 2.0 | | | | | |
| Pre-tax income | -27.3 | -36.0 | -56.9 | -30.8 | -17.8 | -4.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Earnings from continuing ops | -27.3 | -36.0 | -57.0 | -30.8 | -17.8 | -4.2 |
| Earnings from discontinued ops | 2.2 | | | | | |
| Net income | -25.1 | -36.0 | -57.0 | -30.8 | -17.8 | -4.2 |
| Net margin | -113954.5% | -818.3% | -791.2% | -492.8% | -302.6% | -70.3% |
| |
| Basic EPS [+] | ($5.39) | ($21.22) | ($108.28) | ($3.34) | ($2.35) | ($0.60) |
| Growth | -74.6% | -80.4% | 3141.6% | 41.9% | 289.5% | |
| Diluted EPS [+] | ($5.39) | ($21.22) | ($108.28) | ($3.34) | ($2.35) | ($0.60) |
| Growth | -74.6% | -80.4% | 3141.6% | 41.9% | 289.5% | |
| |
| Shares outstanding (basic) [+] | 5.1 | 1.7 | 0.5 | 9.2 | 7.5 | 7.0 |
| Growth | 197.5% | 223.0% | -94.3% | 22.3% | 8.5% | |
| Shares outstanding (diluted) [+] | 5.1 | 1.7 | 0.5 | 9.2 | 7.5 | 7.0 |
| Growth | 197.5% | 223.0% | -94.3% | 22.3% | 8.5% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|